Profile data is unavailable for this security.
About the company
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
- Revenue in USD (TTM)4.16bn
- Net income in USD-368.48m
- Incorporated2005
- Employees2.80k
- LocationJazz Pharmaceuticals PLCFifth FloorWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
- Phone+353 16347800
- Fax+353 16347850
- Websitehttps://www.jazzpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | JAZZ:NSQ since announced | Transaction value |
|---|---|---|
| Chimerix Inc | 19.69% | 929.21m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | 471.79m | -41.42m | 5.33bn | 355.00 | -- | 18.12 | -- | 11.29 | -0.8613 | -0.8613 | 9.26 | 5.69 | 0.6494 | 4.15 | 5.37 | 1,465,199.00 | -5.70 | -29.54 | -7.04 | -34.57 | 79.92 | -- | -8.78 | -92.71 | 3.16 | -22.48 | 0.5144 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
| PTC Therapeutics, Inc. | 1.78bn | 751.72m | 5.58bn | 939.00 | 8.14 | -- | 7.11 | 3.13 | 8.53 | 8.53 | 21.64 | -1.95 | 0.7932 | 1.28 | 8.83 | 1,894,728.00 | 33.51 | -26.68 | 49.97 | -34.84 | 96.83 | 93.49 | 42.25 | -74.67 | 2.26 | 6.03 | 1.07 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.54bn | 283.00 | -- | 43.94 | -- | 37.54 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 8.02bn | 275.00 | 41.49 | 7.04 | 39.21 | 21.48 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.14bn | 683.00 | -- | 123.65 | -- | 16.28 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.34bn | 350.00 | 16.70 | 18.53 | 13.79 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.11bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.34 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.50bn | 3.04k | 22.44 | 1.90 | 19.07 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 12.46bn | 2.00k | 26.62 | 3.82 | 24.49 | 4.35 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.49bn | 9.00k | 350.88 | 1.85 | 17.69 | 2.72 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.50bn | 725.00 | -- | -- | -- | 40.99 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
Data as of Feb 13 2026. Currency figures normalised to Jazz Pharmaceuticals PLC's reporting currency: US Dollar USD
43.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.45m | 8.97% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.96m | 8.17% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 2.67m | 4.39% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.48m | 4.09% |
| LSV Asset Managementas of 31 Dec 2025 | 2.46m | 4.04% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.84m | 3.02% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.82m | 2.99% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 1.71m | 2.81% |
| Fuller & Thaler Asset Management, Inc.as of 31 Dec 2025 | 1.68m | 2.76% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 1.34m | 2.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
